Press Releases

September 16, 2020
CSIR and Aurobindo Pharma to collaborate for COVID-19 vaccine development

September 15, 2020
BIRAC supports Aurobindo Pharma Limited’s COVID-19 vaccine development

August 31, 2020
Auro Vaccines promotes Michael Egan to Chief Scientific Officer

August 14, 2020
Aurobindo Pharma expects Phase I and II trials of COVID-19 vaccine by end of 2020

August 8, 2020
Aurobindo Pharma joins COVID-19 vaccine hunt

March 27, 2020
Auro Vaccines publishes Phase I clinical trial safety and immunogenicity data on its VesiculoVax™-vectored Ebola vaccine in the journal Lancet Infectious Diseases

February 11, 2020
Aurobindo Pharma Acquires Certain Assets of Profectus BioSciences

September 20, 2018
Profectus BioSciences and the NIAID HIV Vaccine Trials Network publishes Phase I clinical trial safety and tolerability data on its PBS Vax™ HIV vaccine in the journal PLoS One, 2018 Sep 20;13(9):e0202753.

May 24, 2018
CEPI Awards $25 Million Contract to Profectus BioSciences and Emergent BioSolutions to Develop Nipah Virus Vaccine
(transferred to Auro Vaccines)

October 2, 2017
Profectus BioSciences Awarded NIH Contract for up to $22.25 Million to Develop Multi-Component Vaccine for Ebola, Marburg, and Lassa Viruses
(transferred to Auro Vaccines)